Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern

Rajesh Vikkurthi, Asgar Ansari, Anupama R Pai, Someshwar Nath Jha, Shilpa Sachan, Suvechchha Pandit, Bhushan Nikam, Anurag Kalia, Bimal Prasad Jit, Hilal Ahmad Parray, Savita Singh, Pallavi Kshetrapal, Nitya Wadhwa, Tripti Shrivastava, Poonam Coshic, Suresh Kumar, Pragya Sharma, Nandini Sharma, Juhi Taneja, Anil K Pandey, Ashok Sharma, Ramachandran Thiruvengadam, Alba Grifoni, Shinjini Bhatnagar, Daniela Weiskopf, Alessandro Sette, Pramod Kumar Garg, Nimesh Gupta
doi: https://doi.org/10.1101/2021.11.14.21266294
Rajesh Vikkurthi
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asgar Ansari
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anupama R Pai
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Someshwar Nath Jha
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shilpa Sachan
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suvechchha Pandit
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhushan Nikam
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anurag Kalia
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bimal Prasad Jit
2Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilal Ahmad Parray
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Singh
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pallavi Kshetrapal
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nitya Wadhwa
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tripti Shrivastava
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poonam Coshic
4Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suresh Kumar
5Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, 110002, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Sharma
5Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, 110002, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nandini Sharma
5Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, 110002, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juhi Taneja
6ESIC Medical College and Hospital, Faridabad, 121012, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil K Pandey
6ESIC Medical College and Hospital, Faridabad, 121012, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashok Sharma
2Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramachandran Thiruvengadam
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alba Grifoni
7Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinjini Bhatnagar
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Weiskopf
7Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Sette
7Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA
8Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, 92037, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pramod Kumar Garg
3Translational Health Science and Technology Institute, Faridabad, 121001, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nimesh Gupta
1Vaccine Immunology Laboratory, National Institute of Immunology, New Delhi, 110067, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nimesh.gupta@nii.ac.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The characteristics of immune memory established in response to inactivated SARS-CoV-2 vaccines remains unclear. We determined the magnitude, quality and persistence of cellular and humoral memory responses up to 6 months after vaccination with BBV152/Covaxin. Here, we show that the quantity of vaccine-induced spike- and nucleoprotein-antibodies is comparable to that following natural infection and the antibodies are detectable up to 6 months. The RBD-specific antibodies decline in the range of 3 to 10-fold against the SARS-CoV-2 variants in the order of alpha (B.1.1.7) > delta (B.1.617.2) > beta (B.1.351), with no observed impact of gamma (P.1) and kappa (B.1.617.1) variant. We found that the vaccine induces memory B cells, similar to natural infection, which are impacted by virus variants in the same order as antibodies. The vaccine further induced antigen-specific functionally potent multi-cytokine expressing CD4+ T cells in ∼85% of the subjects, targeting spike and nucleoprotein of SARS-CoV-2. Marginal ∼1.3 fold-reduction was observed in vaccine-induced CD4+ T cells against the beta variant, with no significant impact of the alpha and the delta variants. The antigen-specific CD4+ T cells were populated in the central memory compartment and persisted up to 6 months of vaccination. Importantly the vaccine generated Tfh cells that are endowed with B cell help potential, similar to the Tfh cells induced after natural infection. Altogether, these findings establish that the inactivated virus vaccine BBV152 induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least 6 months after vaccination. This study provides insight into the attributes of BBV152-elicited immune memory, and has implication for future vaccine development, guidance for use of inactivated virus vaccine, and booster immunization.

Competing Interest Statement

NG, AA are listed as inventor on procedure patent application no. 202111003148, submitted by National Institute of Immunology, that covers the use of T-cell qualitative assessment method for vaccine evaluation and adjuvant testing purposes. A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. Data and materials availability: All data are available in the main text or the extended data.

Funding Statement

This work was financially supported by the Science and Engineering Research Board, DST grant (IPA/2020/000077) to NG, Department of Biotechnology (DBT) grant (BT/PR30223/MED/2018) to NG and the core grant of National Institute of Immunology. COVID-19 Bioresource grant (BT/PR40401/BIOBANK/03.2020) to Translational Health Science and Technology Institute. Further support provided in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocols were approved by the Human Research Ethics Committees of National Institute of Immunology and the partnering institutions.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available in the main text or the extended data

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 15, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
Rajesh Vikkurthi, Asgar Ansari, Anupama R Pai, Someshwar Nath Jha, Shilpa Sachan, Suvechchha Pandit, Bhushan Nikam, Anurag Kalia, Bimal Prasad Jit, Hilal Ahmad Parray, Savita Singh, Pallavi Kshetrapal, Nitya Wadhwa, Tripti Shrivastava, Poonam Coshic, Suresh Kumar, Pragya Sharma, Nandini Sharma, Juhi Taneja, Anil K Pandey, Ashok Sharma, Ramachandran Thiruvengadam, Alba Grifoni, Shinjini Bhatnagar, Daniela Weiskopf, Alessandro Sette, Pramod Kumar Garg, Nimesh Gupta
medRxiv 2021.11.14.21266294; doi: https://doi.org/10.1101/2021.11.14.21266294
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
Rajesh Vikkurthi, Asgar Ansari, Anupama R Pai, Someshwar Nath Jha, Shilpa Sachan, Suvechchha Pandit, Bhushan Nikam, Anurag Kalia, Bimal Prasad Jit, Hilal Ahmad Parray, Savita Singh, Pallavi Kshetrapal, Nitya Wadhwa, Tripti Shrivastava, Poonam Coshic, Suresh Kumar, Pragya Sharma, Nandini Sharma, Juhi Taneja, Anil K Pandey, Ashok Sharma, Ramachandran Thiruvengadam, Alba Grifoni, Shinjini Bhatnagar, Daniela Weiskopf, Alessandro Sette, Pramod Kumar Garg, Nimesh Gupta
medRxiv 2021.11.14.21266294; doi: https://doi.org/10.1101/2021.11.14.21266294

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9772)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2312)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1561)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11649)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1179)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4661)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)